Related Experiment Video
Updated: May 12, 2026
09:37
Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure
Published on: December 2, 2014
Left ventricular remodelling after acute myocardial infarction--solved and unsolved issues
1Service de Cardiologie, Hospital Saint Jacques, Besancon, France.
European Heart Journal
|August 1, 1995
Summary
Left ventricular remodelling post-myocardial infarction can lead to heart failure. Interventions targeting the renin-angiotensin system show promise in limiting this remodelling and reducing mortality, though optimal strategies require further study.
Area of Science:
- Cardiology
- Cardiovascular Research
- Pharmacology
Background:
- Left ventricular remodelling following acute myocardial infarction (MI) can lead to progressive left ventricular dysfunction and congestive heart failure.
- The renin-angiotensin system (RAS) plays a critical role in mediating these adverse remodelling processes.
- While RAS inhibition has shown benefits, optimal therapeutic strategies and patient selection remain areas of active investigation.
Purpose of the Study:
- To review the mechanisms of left ventricular remodelling after acute MI.
- To discuss the role of the renin-angiotensin system in this process.
- To evaluate the current evidence and controversies surrounding pharmacological interventions, particularly ACE inhibitors, in managing post-MI remodelling and heart failure.
Main Methods:
- Review of existing literature on left ventricular remodelling after acute myocardial infarction.
- Analysis of the impact of systemic and tissue renin-angiotensin systems.
- Evaluation of clinical trial data on pharmacological interventions, focusing on ACE inhibitors.
Main Results:
- Key predictors of late left ventricular function impairment include akinetic surface >20%, left ventricular ejection fraction <40%, anterior MI location, low stroke volume, and persistent infarct artery occlusion.
- ACE inhibitors have demonstrated benefits in reducing mortality and limiting remodelling, particularly in patients with low ejection fraction.
- Controversies persist regarding the optimal timing of ACE inhibitor initiation, combination therapy with thrombolytics, and the role of angioplasty.
Conclusions:
- Left ventricular remodelling is a critical determinant of long-term outcomes after acute MI.
- Understanding predictors of LV dysfunction aids in identifying high-risk patients.
- Further research is needed to optimize RAS-targeted therapies and address current clinical controversies to improve post-MI patient management.
Related Concept Videos
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:26Imbalances in Cardiac Output
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...